Foam sclerotherapy vs liquid sclerotherapy
QoL · participants with varicose veinsa
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
99 questions · 101 findings · 5 reviews
No studies found 37 · 36.6%GRADE not reported 6 · 5.9%Very low 16 · 15.8%Low 18 · 17.8%Moderate 24 · 23.8%High 0 · 0%
Foam sclerotherapy vs liquid sclerotherapy
Persistence of symptoms · participants with varicose veinsa
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Foam sclerotherapy vs liquid sclerotherapy
Recurrent varicose veins · participants with varicose veinsa
It is very uncertain whether foam sclerotherapy changes recurrent varicose veins compared with liquid sclerotherapy (very low certainty).
1 finding from 1 review
- RR 1.1 [0.86, 1.42]1 study · 286 participantsVery low
Foam sclerotherapy vs foam sclerotherapy
Cosmetic appearance · participants with varicose veinsa
It is very uncertain whether foam sclerotherapy changes cosmetic appearance (self‐described cosmetic improvement) compared with foam sclerotherapy (very low certainty).
1 finding from 1 review
- RR 1.11 [0.84, 1.47]1 study · 80 participantsVery low
Foam sclerotherapy vs foam sclerotherapy
Number of thromboembolic complications · participants with varicose veinsa
It is very uncertain whether foam sclerotherapy changes complications ‐ thromboembolic compared with foam sclerotherapy (very low certainty).
1 finding from 1 review
- RR 1.47 [0.41, 5.33]3 studies · 371 participantsVery low
Foam sclerotherapy vs foam sclerotherapy
Residual varicose veins · participants with varicose veinsa
Foam sclerotherapy showed no clear difference in residual varicose veins compared with foam sclerotherapy (moderate certainty).
1 finding from 1 review
- RR 0.67 [0.43, 1.04]3 studies · 371 participantsModerate
Sclerotherapy vs placebo
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
- no estimate extracted4 studies · 613 participantsModerate
Sclerotherapy vs placebo
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy probably leads to higher adverse events ‐ hyperpigmentation ( compared with placebo (moderate certainty).
1 finding from 1 review
- RR 11.88 [4.54, 31.09]3 studies · 528 participantsModerate
Sclerotherapy vs placebo
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy probably leads to higher adverse events ‐ matting ( compared with placebo (moderate certainty).
1 finding from 1 review
- RR 4.06 [1.28, 12.84]3 studies · 528 participantsModerate
Sclerotherapy vs placebo
Pain ( · people with telangiectasias and reticular veins
1 finding from 1 review
- no estimate extracted1 study · 40 participantsLow
Sclerotherapy vs placebo
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Sclerotherapy vs placebo
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Sclerotherapy vs placebo
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins
1 finding from 1 review
- no estimate extracted4 studies · 473 participantsModerate
Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (STS) probably leads to higher adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
- RR 1.71 [1.1, 2.64]4 studies · 478 participantsModerate
Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (STS) probably leads to higher adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
- RR 2.1 [1.14, 3.85]2 studies · 323 participantsModerate
Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Pain ( · people with telangiectasias and reticular veins
Sclerotherapy (STS) showed no clear difference in pain ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
- RR 1.49 [0.99, 2.25]4 studies · 409 participantsModerate
Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Sclerotherapy (STS) vs sclerotherapy (any sclerosant)
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found